The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience
| Autor: | Annelies E. de Weerd, Willem Weimar, Michiel G. H. Betjes, Madelon van Agteren, Jan N. M. IJzermans, Peter A. W. te Boekhorst, Jaqueline van de Wetering |
|---|---|
| Přispěvatelé: | Internal Medicine, Hematology, Surgery |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Kidney
medicine.medical_specialty Article Subject business.industry lcsh:Surgery Antibody titer lcsh:RD1-811 medicine.disease Single Center Surgery Transplantation medicine.anatomical_structure surgical procedures operative ABO blood group system Immunology medicine Clinical Study Rituximab Immunoadsorption business Kidney transplantation medicine.drug |
| Zdroj: | Journal of Transplantation Journal of Transplantation, 2014:913902 Journal of Transplantation, Vol 2014 (2014) |
| ISSN: | 2090-0007 |
| DOI: | 10.1155/2014/913902 |
| Popis: | This study describes the single center experience and long-term results of ABOi kidney transplantation using a pretransplantation protocol involving immunoadsorption combined with rituximab, intravenous immunoglobulins, and triple immune suppression. Fifty patients received an ABOi kidney transplant in the period from 2006 to 2012 with a follow-up of at least one year. Eleven antibody mediated rejections were noted of which 5 were mixed antibody and cellular mediated rejections. Nine cellular mediated rejections were recorded. Two grafts were lost due to rejection in the first year. One-year graft survival of the ABOi grafts was comparable to 100 matched ABO compatible renal grafts, 96% versus 99%. At 5-year follow-up, the graft survival was 90% in the ABOi versus 97% in the control group. Posttransplantation immunoadsorption was not an essential part of the protocol and no association was found between antibody titers and subsequent graft rejection. Steroids could be withdrawn safely 3 months after transplantation. Adverse events specifically related to the ABOi protocol were not observed. The currently used ABOi protocol shows good short and midterm results despite a high rate of antibody mediated rejections in the first years after the start of the program. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|